Oncolytics Biotech Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: May 16, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, regulatory
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed a 6-K, confirming foreign private issuer status and 20-F reporting.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on May 16, 2024, to report its status as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and is involved in the pharmaceutical preparations industry. This filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing confirms Oncolytics Biotech's status as a foreign private issuer and its reporting obligations with the SEC, which is important for investors tracking the company's regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming the company's reporting status and does not contain new financial or operational information.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer of the report
- 001-38512 (company) — SEC File Number for Oncolytics Biotech Inc.
- 20240516 (date) — Filing date of the report
- May 2024 (date) — Reporting period for the Form 6-K
- Calgary, Alberta, Canada (location) — Principal executive offices of Oncolytics Biotech Inc.
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filing serves to report the status of Oncolytics Biotech Inc. as a foreign private issuer and to indicate that it files annual reports under Form 20-F.
When was this Form 6-K filed?
This Form 6-K was filed on May 16, 2024.
What is the SEC file number for Oncolytics Biotech Inc.?
The SEC file number for Oncolytics Biotech Inc. is 001-38512.
Where are Oncolytics Biotech Inc.'s principal executive offices located?
Oncolytics Biotech Inc.'s principal executive offices are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
Does Oncolytics Biotech Inc. file its annual reports on Form 40-F?
No, the filing indicates that Oncolytics Biotech Inc. files its annual reports under Form 20-F, not Form 40-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2024-05-16 11:00:15
Filing Documents
- form6k2024agm.htm (6-K) — 18KB
- agm2024votingresultspr.htm (EX-99.1) — 24KB
- 0001129928-24-000042.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date May 16, 2024 Kirk Look Chief Financial Officer